Abstract:Coronavirus disease-2019 (COVID-19), caused by SARS-CoV-2, has rapidly spread to most of countries in the world, threatening the health and lives of many people. Unfortunately, information regarding the immunological characteristics in COVID-19 patients remains limited. Here we collected the blood samples from 18 healthy donors (HD) and 38 COVID-19 patients to analyze changes in the adaptive immune cell populations and phenotypes. In comparison to HD, the lymphocyte percentage was slightly decreased, the percentages of CD4 and CD8 T cells in lymphocytes are similar, whereas B cell percentage increased in COVID-19 patients. T cells, especially CD8 T cells, showed an enhanced expression of late activation marker CD25 and exhaustion marker PD-1. Importantly, SARS-CoV-2 induced an increased percentage of T follicular helpher (Tfh)- and germinal center B-like (GCB-like) cells in the blood. However, the parameters in COVD-19 patients remained unchanged across various age groups. Therefore, we demonstrated that the T and B cells can be activated normally and exhibit functional features. These data provide a clue that the adaptive immunity in most people could be primed to induce a significant immune response against SARS-CoV-2 infection upon receiving standard medical care. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial COVID-19 infection was excluded from clinical trial registrition. ### Funding Statement This work was supported by grants from Natural Science Foundation of China (No. 81820108017), Natural Science Foundation of China (No. 81771673), and COVID-19 special project of Xi'an Jiaotong University Foundation (xzy032020002). We thank all the doctors, nurses, public health workers, and patients for their contribution against SARS-CoV-2 infection. ### Author Declarations All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript. Yes All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All the data are available in the manuscript.

Single-cell RNA sequencing reveals ex vivo signatures of SARS-CoV-2-reactive T cells through ‘reverse phenotyping’

Single-cell RNA sequencing reveals<i>in vivo</i>signatures of SARS-CoV-2-reactive T cells through ‘reverse phenotyping’

Analysis of adaptive immune cell populations and phenotypes in the patients infected by SARS CoV 2

Overly Exuberant Innate Immune Response to SARS-CoV-2 Infection

Human SARS-CoV-2 challenge uncovers local and systemic response dynamics

Characterization of SARS-CoV-2 public CD4+ αβ T cell clonotypes through reverse epitope discovery

Characteristics of SARS-CoV-2-specific cytotoxic T cells revealed by single-cell immune profiling of longitudinal COVID-19 blood samples

Identification of SARS-CoV-2-specific T cell and its receptor

Multimodal single-cell datasets characterize antigen-specific CD8+ T cells across SARS-CoV-2 vaccination and infection

Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Combined assessment of S- and N-specific IL-2 and IL-13 secretion and CD69 neo-expression for discrimination of post-infection and post-vaccination cellular SARS-CoV-2-specific immune response

Single Cell and Immune Repertoire Profiling of COVID-19 Patients Reveal Novel Therapeutic Candidates

T cell receptor repertoires in patients with COVID-19 reveal disease severity signatures

T cell receptor β repertoires in patients with COVID-19 reveal disease severity signatures

Perturbations of the T-cell receptor repertoire in response to SARS-CoV-2 in immunocompetent and immunocompromised individuals

Identification of Cross-Reactive CD8+ T Cell Receptors with High Functional Avidity to a SARS-CoV-2 Immunodominant Epitope and Its Natural Mutant Variants

Single-cell Transcriptome Landscape and Antigen Receptor Dynamic During SARS-CoV-2 Vaccination

HLA-A∗02:01 restricted T cell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses

A T-Cell-Derived 3-Gene Signature Distinguishes SARS-CoV-2 from Common Respiratory Viruses

In-depth analysis of human virus-specific CD8+ T cells delineates unique phenotypic signatures for T cell specificity prediction